By Week 12 , more mavrilimumab - versus placebo-treated subjects achieved a DAS28-CRP response ( 50.0 % vs. 23.5 % , p = 0.081 ) ; a significant response was seen in the 30 mg and 100 mg dose groups ( both 75.0 % vs. 23.5 % , p = 0.028 ) .